Translational Pediatric Sarcoma Research

We aim at uncovering disease mechanisms that can be used diagnostically and therapeutically to improve the long-term chances of recovery of our young patients. The focus lies on new methods that are essential for correct diagnosis and the choice of the best possible therapy. We also investigate less aggressive therapies and new approaches to overcome drug resistance of tumors. 

To accomplish our mission, the division Translational Pediatric Sarcoma Research is comprised of three teams whose collaboration gives way to synergetic effects: 

The team Translational Genomics (Prof. Dr. Dr. T. Grünewald & Dr. Dr. Dr. Jing Li) systematically establishes multi-dimensional omics-datasets of a large number of pediatric sarcomas and correlates molecular alterations with clinical data to identify new driver mutations, disease-relevant drug targets and prognostic/predictive biomarkers, and to create resources for hypothesis generation and functional validation for future projects.

The team Mechanisms of Cancer Progression (Dr. F. Cidre-Aranaz) aims at deconvoluting the multilayered process underlying cancer progression and metastasis. For this purpose, systems biology approaches based on multi-omics data and clinical information with functional in vitro and in vivo experiments will be combined to identify treatable vulnerabilities in pediatric sarcomas that can prevent metastasis.

The team Innovative Therapies (Dr. S. Ohmura) is investigating potential therapeutic targets for pediatric sarcomas in preclinical models. The focus here lies in developing and testing new targeted therapy approaches, including immunotherapy, that enable more effective therapy with fewer side effects, especially for patients with chemo resistant tumors.